The Neurosurgery Signal — Signal, Not Noise

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1001/jama.2012.220

PMID

22396514

PICO

Population

Patients aged ≥12 years with mesial temporal lobe epilepsy (MTLE) and disabling seizures for ≤2 consecutive years after failure of 2 brand-name antiepileptic drug trials.

Intervention

Anteromesial temporal resection (AMTR) plus antiepileptic drug treatment.

Comparator

Continued antiepileptic drug treatment alone.

Outcomes

Freedom from disabling seizures during year 2 of follow-up, health-related quality of life (QOLIE-89), cognitive function, social adaptation.

Design

Type

Multicenter randomized controlled trial

Randomized

Yes

Multicenter

Yes

Blinded

Not applicable: surgical vs medical therapy cannot be blinded to participants or clinicians.

Follow-up

2 years

Primary endpoint

Freedom from disabling seizures during year 2 of follow-up.

Secondary endpoints

Change in Quality of Life in Epilepsy 89 (QOLIE-89) overall T-score
Cognitive function
Social adaptation

Practice impact

What this means

This RCT compared early surgery versus continued meds for MTLE within 2 years of drug failure. Surgery yielded 73% seizure freedom at 2 years vs 0% with meds alone (p<0.001). Quality of life improved more with surgery in sensitivity analysis. The trial was stopped early (n=38 vs planned 200), so results are promising but require cautious interpretation due to limited power.

Bottom line

Early surgery for drug-resistant MTLE within 2 years of diagnosis significantly increases seizure freedom compared to continued medical therapy alone.

Strength of evidence

moderate

Recommendation

consider change

Why it matters

Randomized design provides high internal validity for seizure outcome.
Premature termination and small sample size reduce confidence in quality of life and cognitive outcomes.
Large treatment effect for seizure freedom (73% vs 0%) is clinically meaningful.

What would change my mind

Larger RCT confirming these findings with adequate power for secondary outcomes.
Long-term follow-up data demonstrating sustained seizure freedom and cognitive safety.
Cost-effectiveness analysis supporting early surgical intervention.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

High risk: trial halted prematurely due to slow accrual (planned n=200, actual n=38), leading to underpowered analyses.

Confounding

Low risk: randomization performed, but 7/23 medical group participants crossed over to surgery before follow-up end, complicating intention-to-treat analysis.

Missing data

Low risk: no indication of substantial missing outcome data in reported results.

Multiplicity

Low risk: primary outcome clearly defined; secondary analyses appropriately adjusted.

Notes

Premature termination limits statistical power and precision of estimates.
Crossover from medical to surgical group occurred, addressed in sensitivity analyses.

Stats check

NNT

NNT = 1.4 for seizure freedom (based on 73% vs 0% absolute risk difference)

Effect sizes

Odds ratio = ∞ (95% CI 11.8 to ∞) for seizure freedom
Treatment effect on QOLIE-89 = 8.5 points (95% CI -1.0 to 18.1) in intention-to-treat analysis

Absolute effects

0/23 (0%) seizure-free in medical group vs 11/15 (73%) in surgical group during year 2
Mean QOLIE-89 improvement: 12.6 points surgical vs 4.0 points medical

Concerns

Wide confidence intervals due to small sample size (n=38).
Primary outcome p<0.001 but CI extends to infinity due to zero events in medical group.

External validity

Who it applies to

Patients with newly intractable MTLE (≤2 years of drug resistance) who are candidates for standardized anteromesial temporal resection.

Who it does not

Patients with extratemporal epilepsy, non-lesional MTLE, or chronic drug resistance >2 years.

Generalizability notes

Recruitment at 16 US epilepsy surgery centers suggests broad applicability within defined criteria.
Strict inclusion criteria (e.g., brand-name AED trials) may limit applicability to real-world settings.

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 1 Results

quote

Planned enrollment was 200, but the trial was halted prematurely due to slow accrual.

claim_id

stats_check.effect_sizes

locator

p. 1 Results

quote

Zero of 23 participants in the medical group and 11 of 15 in the surgical group were seizure free during year 2 of follow-up (odds ratio = ∞; 95% CI, 11.8 to ∞; P < .001).

claim_id

practice_impact.bottom_line

locator

p. 1 Results

quote

Among patients with newly intractable disabling MTLE, resective surgery plus AED treatment resulted in a lower probability of seizures during year 2 of follow-up than continued AED treatment alone.

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years